

***Case No COMP/M.5723 -  
WARBURG PINCUS/  
NOVO/ ARCHIMEDES  
PHARMA JV***

Only the English text is available and authentic.

**REGULATION (EC) No 139/2004  
MERGER PROCEDURE**

---

Article 6(1)(b) NON-OPPOSITION  
Date: 22/01/2010

***In electronic form on the EUR-Lex website under document  
number 32010M5723***



EUROPEAN COMMISSION

Brussels, 22/01/2010  
SG-Greffe(2010) D/502/503  
C(2010) 467

PUBLIC VERSION

MERGER PROCEDURE  
ARTICLE 6(1)(b) DECISION

SIMPLIFIED PROCEDURE

**To the notifying parties:**

Dear Madam(s) and/or Sir(s),

**Subject: Case No COMP/M.5723 - WARBURG PINCUS/ NOVO/ ARCHIMEDES PHARMA JV**  
**Notification of 11/12/2009 pursuant to Article 4 of Council Regulation (EC) No 139/2004<sup>1</sup>**  
**Publication in the Official Journal of the European Union No C 320, 24.12.2009, p.26**

1. On 11. December 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 of the EC Merger Regulation by which the undertakings Warburg Pincus Private Equity VIII OP and Warburg Pincus International Partners LP, controlled by Warburg Pincus & Co., USA, ("Warburg Pincus") and Novo Nordisk A/S and Novozymes A/S, wholly owned by the Novo Nordisk Foundation, Denmark, ("Novo") acquire within the meaning of Article 3(1)(b) of the EC Merger Regulation joint control of Archimedes Pharma Ltd., United Kingdom, ("Archimedes") by way of purchase of shares.
2. The business activities of the undertakings concerned are:
  - for Warburg Pincus: A US based global private equity investor with investments focused on a range of sectors, including healthcare;
  - for Novo: An institution that supports research in health science and art history primarily through the award of grants;

---

<sup>1</sup> OJ L 24, 29.1.2004, p. 1 (the "EC Merger Regulation").

- for Archimedes: A hospital-focused specialty pharmaceutical group with established commercial operations and a portfolio of products focused on oncology, pain, neurology and critical care.
3. After examination of the notification, the Commission has concluded that the notified operation falls within the scope of the EC Merger Regulation and of paragraph 5(c) of the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004<sup>2</sup>.
  4. For the reasons set out in the Notice on a simplified procedure, the Commission has decided not to oppose the notified operation and to declare it compatible with the common market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the EC Merger Regulation.

For the Commission  
(signed)  
Philip LOWE  
Director General

---

<sup>2</sup> OJ C 56, 05.3.2005, p. 32 ("Notice on a simplified procedure").